These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 34199304)

  • 61. [Pharmacological characteristics and clinical effectiveness of Futibatinib (Lytgobi
    Takagaki K; Okude R; Hirayama N; Sootome H; Hirai H
    Nihon Yakurigaku Zasshi; 2024 Nov; 159(6):423-432. PubMed ID: 39384389
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
    D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
    Lassman AB; Sepúlveda-Sánchez JM; Cloughesy TF; Gil-Gil MJ; Puduvalli VK; Raizer JJ; De Vos FYF; Wen PY; Butowski NA; Clement PMJ; Groves MD; Belda-Iniesta C; Giglio P; Soifer HS; Rowsey S; Xu C; Avogadri F; Wei G; Moran S; Roth P
    Clin Cancer Res; 2022 Jun; 28(11):2270-2277. PubMed ID: 35344029
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis.
    Rouvinov K; Levanon E; Peer A; Sarfaty M; Sarid D; Neiman V; Grikshtas E; Rosenbaum E; Kushnir I; Talmor B; Friger M; Zarbiv Y; Gez E; Dresler H; Shalata W; Meirovitz A; Shrem NS; Yakobson A; Mermershtain W; Keizman D
    Front Oncol; 2023; 13():1151701. PubMed ID: 37293597
    [TBL] [Abstract][Full Text] [Related]  

  • 65. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
    Katoh M
    Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
    Qin Q; Patel V; Galsky MD
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
    Merz V; Zecchetto C; Melisi D
    Future Oncol; 2021 Feb; 17(4):389-402. PubMed ID: 33034201
    [TBL] [Abstract][Full Text] [Related]  

  • 68. FGFR Inhibition in Urothelial Carcinoma.
    Li R; Linscott J; Catto JWF; Daneshmand S; Faltas BM; Kamat AM; Meeks JJ; Necchi A; Pradere B; Ross JS; van der Heijden MS; van Rhijn BWG; Loriot Y
    Eur Urol; 2024 Sep; ():. PubMed ID: 39353825
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients.
    Meric-Bernstam F; Hollebecque A; Furuse J; Oh DY; Bridgewater JA; Shimura M; Anderson B; Hangai N; Wacheck V; Goyal L
    Clin Cancer Res; 2024 Apr; 30(8):1466-1477. PubMed ID: 38329716
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Erdafitinib for the treatment of metastatic bladder cancer.
    Montazeri K; Bellmunt J
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
    [No Abstract]   [Full Text] [Related]  

  • 71. Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis.
    Zheng X; Wang H; Deng J; Yao M; Zou X; Zhang F; Ma X
    Front Oncol; 2022; 12():907377. PubMed ID: 36776367
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Erdafitinib: First Global Approval.
    Markham A
    Drugs; 2019 Jun; 79(9):1017-1021. PubMed ID: 31161538
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Erdafitinib to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2019 Aug; 55(8):495-501. PubMed ID: 31461086
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A novel bioanalytical method for the quantification of pemigatinib in rat plasma by UPLC-MS/MS.
    Weng Q; Tan W; Yu RY; Xu RA; Chen Y
    J Pharm Biomed Anal; 2021 Aug; 202():114137. PubMed ID: 34015593
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain
    Franza A; Pirovano M; Giannatempo P; Cosmai L
    Future Oncol; 2022 Jun; 18(19):2455-2464. PubMed ID: 35387485
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.
    Karkera JD; Cardona GM; Bell K; Gaffney D; Portale JC; Santiago-Walker A; Moy CH; King P; Sharp M; Bahleda R; Luo FR; Alvarez JD; Lorenzi MV; Platero SJ
    Mol Cancer Ther; 2017 Aug; 16(8):1717-1726. PubMed ID: 28416604
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements.
    Walden D; Eslinger C; Bekaii-Saab T
    Therap Adv Gastroenterol; 2022; 15():17562848221115317. PubMed ID: 35967919
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma.
    Alekseev O; Ojuok E; Cousins S
    Int J Retina Vitreous; 2021 Apr; 7(1):34. PubMed ID: 33892812
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Targeting FGFR inhibition in cholangiocarcinoma.
    Goyal L; Kongpetch S; Crolley VE; Bridgewater J
    Cancer Treat Rev; 2021 Apr; 95():102170. PubMed ID: 33735689
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
    Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
    J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.